Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's Disease (PD) diagnosed between the ages of 30 and 85 years;~* Hoehn and Yahr Stage 1-3 in an on state;~* Require levodopa-containing medication regimen at least 3 times during the waking day;~* Experience motor fluctuations with a minimum of 2 hours of average daily off time per waking day (excluding early morning off time) and demonstrate levodopa responsiveness;~* Are on stable PD medication regimen;~* Total daily LD dose \<1600 mg/day;~* Able to perform a spirometry maneuver in the ON and OFF states;~* Normal cognition confirmed by MMSE score ≥25~Exclusion Criteria:~* Pregnant or lactating females;~* Previous surgery for PD or plan to have stereotactic surgery during the study period;~* History of psychotic symptoms requiring treatment, or suicide ideation or attempt within last year;~* Known contraindication to the use of levodopa;~* Any significant condition, severe concurrent disease, abnormality or finding that would make patients unsuitable or may compromise patient safety;~* Any contraindication to performing routine spirometry.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CVT-301 Low Dose (Type: EXPERIMENTAL): Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
- CVT-301 High Dose (Type: EXPERIMENTAL): Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
- Placebo (Type: PLACEBO_COMPARATOR): Capsules of inhalation-grade lactose used up to 5 times/day for OFF episodes for 3 months duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).